Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTATOC and 177Lu-DOTATATE: the role of associated risk factors.
Abstract
Purpose Peptide receptor radionuclide therapy (PRRT) of neuroendocrine tumours with (90)Y-DOTATOC and (177)Lu-DOTATATE is promising. The kidney is the critical organ and despite renal protection, function loss may become evident years later. The aim of this study was to analyse renal parameters in patients who had undergone dosimetry before PRRT.Methods Among those in protocols at our institution, 28 patients were considered: 23 received (90)Y-DOTATOC (3.8-29.2 GBq, median 12.2) and five received (177)Lu-DOTATATE (20.7-29.2 GBq, median 23.2). Patients were followed up after therapy for creatinine and creatinine clearance loss (CCL) for 3-97 months (median 30). Renal doses and bio-effective doses (BED) were calculated (MIRD, LQ model).Results After (90)Y-DOTATOC toxicity on creatinine according to NCI criteria occurred in nine cases (seven grade 1, one grade 2, one grade 3), CCL at 1 year was >5% in 12 cases and >10% in eight. A 28-Gy BED threshold was observed in patients with risk factors (mainly hypertension and diabetes), while it was 40 Gy in patients without risk factors. Probably due to the low number of patients, despite the absence of severe toxicity after hyper-fractionated PRRT, clear correlations between fractionation and toxicity could not be found. After (177)Lu-DOTATATE, no toxicity occurred in 1-2 year follow-up; CCL at 1 year >5% occurred in three patients and >10% in two.Conclusions Our results indicate the importance of clinical screening for risk factors: In this case, a BED <28 Gy is recommended. Fractionation of therapy is important in order to decrease toxicity, and further studies are needed to evaluate its clinical impact.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
90Y-PRRT has a small potential of causing renal toxicity when used without nephroprotection, especially in patients with compromised renal function.
“It has been demonstrated that 90Y-PRRT has a small potential of causing renal toxicity when used without nephroprotection, especially in patients with compromised renal function (53, 54).”
From Alpha-peptide receptor radionuclide therapy using actinium-225 labeled somatostatin receptor agonists and antagonists (2022) · cites this paper as [53]
Cites
Assessing Kidney Function — Measured and Estimated Glomerular Filtration Rate
Stevens, L. A., Coresh, J., Greene, T., & Levey, A. S. (2006) · New England Journal of Medicine · doi:10.1056/nejmra054415 · Cited by 2,952 · see citing works
Stabin, M. G., Sparks, R. B., & Crowe, E. A. (2005) · PubMed · Cited by 1,340 · see citing works
Cisplatin Nephrotoxicity: A Review
Yao, X., Panichpisal, K., Kurtzman, N. A., & NUGENT, K. M. (2007) · The American Journal of the Medical Sciences · doi:10.1097/maj.0b013e31812dfe1e · Cited by 1,254 · see citing works
Messerli, F. H., Williams, B., & Ritz, E. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61299-9 · Cited by 683 · see citing works
Kwekkeboom, D. J., Teunissen, J. J., Bakker, W. H., Kooij, P. P., de Herder, W. W., Feelders, R. A., van Eijck, C. H., Esser, J.-P., Kam, B. L., & Krenning, E. P. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.08.066 · Cited by 657 · see citing works
Siegel, J. A., Thomas, S. R., Stubbs, J. B., Mg, S., Hays, M. T., Koral, K. F., Robertson, J. S., Howell, R. W., Wessels, B. W., Fisher, D. R., et al. (1999) · PubMed · Cited by 572 · see citing works
Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq (90)Y-DOTATOC.
Waldherr, C., Pless, M., Maëcke, H. R., et al. (2002) · PubMed · Cited by 446 · see citing works
Valkema, R., de Jong, M., Bakker, W. H., Breeman, W. A. P., Kooij, P. P. M., Lugtenburg, P. J., de Jong, F. H., Christiansen, A., Kam, B. L. R., de Herder, W. W., et al. (2002) · Seminars in Nuclear Medicine · doi:10.1053/snuc/2002.31025 · Cited by 432 · see citing works
Yttrium-90 DOTATOC: first clinical results
Otte, A., Herrmann, R. P., Heppeler, A., Béhé, M. P., Jermann, E., Powell, P., Maëcke, H. R., & Muller, J. (1999) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s002590050476 · Cited by 421 · see citing works
Kwekkeboom, D. J., Mueller‐Brand, J., Paganelli, G., Anthony, L. B., Pauwels, S. A., Kvols, L. K., O’Dorisio, T. M., Valkema, R., Bodei, L., Chinol, M., et al. (2005) · PubMed · Cited by 371 · see citing works
Self-citationSomatostatin receptor-targeted radionuclide therapy of tumors: Preclinical and clinical findings
de Jong, M., Valkema, R., Jamar, F., et al. (2002) · Seminars in Nuclear Medicine · doi:10.1053/snuc.2002.31027 · Cited by 350 · see citing works
Valkema, R., Pauwels, S. A., Kvols, L. K., Kwekkeboom, D. J., Jamar, F., de Jong, M., Barone, R., Walrand, S., Kooij, P. P. M., Bakker, W. H., et al. (2005) · PubMed · Cited by 332 · see citing works
Bodei, L., Cremonesi, M., Zoboli, S., Grana, C. M., Bartolomei, M., Rocca, P. A., Caracciolo, M., Mäcke, H. R., Chinol, M., & Paganelli, G. (2003) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-002-1023-y · Cited by 304 · see citing works
Self-citationBarone, R., Borson‐Chazot, F., Valkema, R., Walrand, S., Chauvin, F., Gogou, L., Kvols, L. K., Krenning, E. P., Jamar, F., & Pauwels, S. A. (2005) · PubMed · Cited by 289 · see citing works
Clinical radiation nephropathy
Cassady, J. R. (1995) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/0360-3016(94)00428-n · Cited by 251 · see citing works
Bodei, L., Cremonesi, M., Grana, C. M., et al. (2004) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-004-1571-4 · Cited by 225 · see citing works
Self-citationReceptor-mediated radiotherapy with 90Y-DOTA-D-Phe1-Tyr3-octreotide
Paganelli, G., Zoboli, S., Cremonesi, M., et al. (2001) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s002590100490 · Cited by 206 · see citing works
Self-citationDosimetry in Peptide radionuclide receptor therapy: a review.
Cremonesi, M., Ferrari, M. E., Bodei, L., et al. (2006) · PubMed · Cited by 203 · see citing works
Self-citationEnd-stage renal disease after treatment with 90 Y-DOTATOC
Cybulla, M., Weiner, S. M., & Otte, A. (2001) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s002590100599 · Cited by 154 · see citing works
Cremonesi, M., Ferrari, M. E., Zoboli, S., et al. (1999) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s002590050462 · Cited by 151 · see citing works
Self-citationD-lysine reduction of indium-111 octreotide and yttrium-90 octreotide renal uptake.
Bernard, B. F., Krenning, E. P., Breeman, W. A. P., et al. (1997) · PubMed · Cited by 146 · see citing works
The Radiobiology of Conventional Radiotherapy and Its Application to Radionuclide Therapy
Dale, R., & Cárabe, A. (2005) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2005.20.47 · Cited by 107 · see citing works
Reduced renal function in patients with simple renal cysts
Alsaid, J., Brumback, M. A., Moghazi, S., et al. (2004) · Kidney International · doi:10.1111/j.1523-1755.2004.00651.x · Cited by 94 · see citing works
Thames, H. D., Ang, K. K., Stewart, F. A., & van der Schueren, E. (1988) · International Journal of Radiation Biology · doi:10.1080/09553008814551461 · Cited by 92 · see citing works
Quantitation in PET using isotopes emitting prompt single gammas: application to yttrium-86
Walrand, S., Jamar, F., Mathieu, I., Camps, J., Lonneux, M., Sibomana, M., Labar, D., Michel, C. J., & Pauwels, S. (2002) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-002-1068-y · Cited by 92 · see citing works
New advances in peptide receptor radionuclide therapy.
de Jong, M., & Krenning, E. P. (2002) · PubMed · Cited by 88 · see citing works
Dale, R. (2004) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/1084978041425070 · Cited by 81 · see citing works
Foster, D. M. (1998) · Advances in experimental medicine and biology · doi:10.1007/978-1-4899-1959-5_4 · Cited by 64 · see citing works
Yamazaki, H., Oi, H., Matsushita, M., et al. (2001) · British Journal of Radiology · doi:10.1259/bjr.74.884.740695 · Cited by 13 · see citing works
Misadministration of Radioactive Material in Medicine: Scientific Background
Wagner, L. K. (1992) · Radiation Research · doi:10.2307/3578447 · Cited by 13 · see citing works
New advances in peptide receptor radionuclide therapy
Jong, M., & Krenning, E. (2002) · EUR Research Repository (Erasmus University Rotterdam) · Cited by 7 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Bodei, L., Kidd, M., Paganelli, G., Grana, C. M., Drozdov, I., Cremonesi, M., Lepensky, C., Kwekkeboom, D. J., Baum, R. P., Krenning, E. P., et al. (2015) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-014-2893-5 · Cited by 465 · see citing works
Self-citationVegt, E., de Jong, M., Wetzels, J. F. M., Masereeuw, R., Melis, M., Oyen, W. J. G., Gotthardt, M., & Boerman, O. C. (2010) · Journal of Nuclear Medicine · doi:10.2967/jnumed.110.075101 · Cited by 334 · see citing works
Garske-Román, U., Sandström, M., Fröss Baron, K., Lundin, L., Hellman, P., Welin, S., Johansson, S., Khan, T., Lundqvist, H., Eriksson, B., et al. (2018) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-018-3945-z · Cited by 254 · see citing works
Okamoto, S., Thieme, A., Allmann, J., D’Alessandria, C., Maurer, T., Retz, M., Tauber, R., Heck, M. M., Wester, H.-J., Tamaki, N., et al. (2017) · Journal of Nuclear Medicine · doi:10.2967/jnumed.116.178483 · Cited by 213 · see citing works
Del Prete, M., Buteau, F.-A., Arsenault, F., Saighi, N., Bouchard, L.-O., Beaulieu, A., & Beauregard, J.-M. (2019) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-018-4209-7 · Cited by 184 · see citing works
Cremonesi, M., Ferrari, M. E., Bodei, L., Chiesa, C., Sarnelli, A., Garibaldi, C., Pacilio, M., Strigari, L., Summers, P. E., Orecchia, R., et al. (2018) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-018-4044-x · Cited by 141 · see citing works
Self-citationShi, M., Jakobsson, V., Greifenstein, L., Khong, P.-L., Chen, X., Baum, R. P., & Zhang, J. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.1034315 · Cited by 68 · see citing works
Role of Artificial Intelligence in Theranostics
Brosch-Lenz, J., Yousefirizi, F., Zukotynski, K., Beauregard, J.-M., Gaudet, V., Saboury, B., Rahmim, A., & Uribe, C. (2021) · PET Clinics · doi:10.1016/j.cpet.2021.06.002 · Cited by 42 · see citing works
Loharkar, S., & Basu, S. (2023) · Expert Review of Precision Medicine and Drug Development · doi:10.1080/23808993.2023.2211090 · Cited by 16 · see citing works
- Authors
- Bodei, L., Cremonesi, M., Ferrari, M., Pacifici, M., Grana, C. M., Bartolomei, M., Baio, S. M., Sansovini, M., & Paganelli, G.
- Affiliations
- European Institute of Oncology (IT)
- Corresponding author
- Bodei, Lisa
- ORCID
- Venue
- European Journal of Nuclear Medicine and Molecular Imaging
- Published
- 2008-04-22
- Volume
- 35
- Issue
- 10
- Pages
- 1847-1856
- ISSN
- 1619-7070 (ISSN-L)
- 1619-7089
- OpenAlex
- W2031048655
- Cited by
- 428
- References
- 31
- Citations by year
- 2026: 20 · 2025: 16 · 2024: 25 · 2023: 17 · 2022: 35 · 2021: 33 · 2020: 24 · 2019: 26 · 2018: 32 · 2017: 27 · 2016: 27 · 2015: 30 · 2014: 17 · 2013: 25 · 2012: 31
- FWCI
- 10.64
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- European Journal of Nuclear Medicine and Molecular Imaging (publishedVersion)
- PubMed (publishedVersion)
- Institutional Research Information System University of Ferrara (University of Ferrara) (submittedVersion)
- Topics
- Health Sciences › Medicine › Epidemiology › Neuroendocrine Tumor Research Advances
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Radiopharmaceutical Chemistry and Applications
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Effects of Radiation Exposure
- Keywords
- peptide receptor radionuclide therapy, nephrotoxicity, 90Y-DOTATOC, 177Lu-DOTATATE, neuroendocrine tumors, risk factors, hypertension, diabetes mellitus, long-term follow-up
- MeSH terms
- Adolescent, Adult, Aged, Body Burden, Female, Humans, Kidney, Kidney Diseases, Longitudinal Studies, Male, Middle Aged, Organometallic Compounds, Radiation Injuries, Risk Factors, Octreotide, Receptors, Peptide, Risk Assessment, Radiopharmaceuticals, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
